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Abstract
Primary schizophreniform psychoses are thought to be caused by complex gene–environment interactions. Secondary forms 
are based on a clearly identifiable organic cause, in terms of either an etiological or a relevant pathogenetic factor. The 
secondary or “symptomatic” forms of psychosis have reentered the focus stimulated by the discovery of autoantibody (Ab)-
associated autoimmune encephalitides (AEs), such as anti-NMDA-R encephalitis, which can at least initially mimic variants 
of primary psychosis. These newly described secondary, immune-mediated schizophreniform psychoses typically present 
with the acute onset of polymorphic psychotic symptoms. Over the course of the disease, other neurological phenomena, 
such as epileptic seizures, movement disorders, or reduced levels of consciousness, usually arise. Typical clinical signs 
for AEs are the acute onset of paranoid hallucinatory symptoms, atypical polymorphic presentation, psychotic episodes in 
the context of previous AE, and additional neurological and medical symptoms such as catatonia, seizure, dyskinesia, and 
autonomic instability. Predominant psychotic courses of AEs have also been described casuistically. The term autoimmune 
psychosis (AP) was recently suggested for these patients. Paraclinical alterations that can be observed in patients with AE/AP 
are inflammatory cerebrospinal fluid (CSF) pathologies, focal or generalized electroencephalographic slowing or epileptic 
activity, and/or suspicious “encephalitic” imaging findings. The antibody analyses in these patients include the testing of 
the most frequently found Abs against cell surface antigens (NMDA-R, CASPR2, LGI1, AMPA-R,  GABAB-R), intracel-
lular antigens (Hu, Ri, Yo, CV2/CRMP5, Ma2 [Ta], amphiphysin, GAD65), thyroid antigens (TG, TPO), and antinuclear 
Abs (ANA). Less frequent antineuronal Abs (e.g., against DPPX,  GABAA-R, glycine-R, IgLON5) can be investigated in the 
second step when first step screening is negative and/or some specific clinical factors prevail. Beyond, tissue-based assays 
on brain slices of rodents may detect previously unknown antineuronal Abs in some cases. The detection of clinical and/or 
paraclinical pathologies (e.g., pleocytosis in CSF) in combination with antineuronal Abs and the exclusion of alternative 
causes may lead to the diagnosis of AE/AP and enable more causal therapeutic immunomodulatory opportunities.
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Background
Schizophrenia and other psychotic disorders are severe and 
frequent conditions characterized by delusions, hallucina-
tions, disorganization, formal thinking changes, catatonia, 
and different negative symptoms typically occurring for 
the first-time during adolescence and early adulthood [65]. 
Primary schizophreniform psychoses are caused by a com-
plex interaction between multiple genes and environmental 
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factors [81]. Large, genome-wide studies have identified 
over 100 distinct gene sites that contribute to the relative risk 
of psychotic symptoms [73]. Secondary forms are based on 
clearly identifiable causes in the sense of etiology or accord-
ing to recognizable pathogenesis [45, 81]. Such secondary 
forms can be linked to autoantibody (Ab)-associated autoim-
mune processes such as anti-N-Methyl-d-aspartate receptor 
[NMDA-R] encephalitis [44]. In 2007, the field of autoim-
mune encephalitis (AE) was redefined with the first descrip-
tion of anti-NMDA-R encephalitis [16, 18, 19]. Since then, a 
large number of other antineuronal Abs against cell surface 
antigens and their associated syndromes have been identified 
[15, 17, 31, 89, 90]. Because these syndromes can be accom-
panied by polymorphic psychotic symptoms, immunological 
concepts of schizophreniform psychoses have gained con-
siderable attention since [1, 6, 15, 22, 36, 67, 68, 76, 77, 78, 
84]. In a German case series of 100 patients with different 
forms of AEs with Abs against antineuronal antigens, over 
half of the patients (60%) presented with psychotic symp-
toms [36]. In most cases that are positive for antineuronal 
Abs, patients develop clear neurological symptoms in the 
course of the disease, such as dystonic movement disorders 
or epileptic seizures [31, 36, 51]. For AE with predomi-
nant psychotic symptoms, the term “autoimmune psycho-
sis” (AP) was recently suggested [21, 61, 67]. The changing 
nomenclature for autoimmune neuropsychiatric phenomena 
is summarized in Box 1.
Box 1: Different nomenclature [6, 22]
Encephalopathy: Traditionally, this term has been used 
mainly for persistent brain damage. The term has also 
been used when secondary brain damage was assumed, 
but the exact mechanism of the disease remained unclear 
(e.g., hepatic or epileptic encephalopathy). Because 
antineuronal autoantibodies (Abs) can now be detected, 
cases of encephalopathy not previously recognized as 
neuroinflammatory can comply with the criteria of auto-
immune encephalitis.
Limbic encephalitis (LE): LE has developed in the 
context of paraneoplastic encephalitis, which has been 
known for some time and has undergone a change in 
meaning in the discourse of the last decade. Originally, 
the term described a clinical focal point syndrome. Cur-
rently, the term is mainly used syndromally, as a descrip-
tion of a clinical syndrome [31].
Autoimmune encephalitis (AE): The term has largely 
established itself as an umbrella term for Ab-associated 
immune-mediated neuropsychiatric syndromes. It is also 
used to describe Ab-negative, probable AE. In an interna-
tional consensus paper from global experts in the field of 
neurology and neuroimmunology, they have suggested a 
clinical approach to the diagnosis of autoimmune enceph-
alitis [31].
Autoimmune psychosis (AP): AP describes a syndrome 
with predominant psychoses and a probable autoimmune 
pathophysiology [21, 61, 67]. Initially, a distinction 
among the following groups was suggested: (1) psychoses 
with detection of classical antineuronal Abs, (2) psycho-
ses associated with systemic inflammatory and autoim-
mune diseases, and (3) Ab-negative AP [61]. The authors 
of a recent expert consensus paper defined criteria for a 
possible, probable, and definite AP [67].
Rationale
The awareness of the fact that psychotic syndromes may 
have autoimmune, Ab-associated causes opens up a new 
field in psychiatry for a small but probable relevant subgroup 
of patients. For clinicians, this raises the question as to how 
far the diagnostic workup and immunomodulating therapy 
attempts should be advanced in individual cases. This arti-
cle investigates this question by illustrating constellations in 
which extended organic diagnostic procedures, especially 
Ab analyses, should be carried out.
Clinical symptomatology
The syndrome of possible autoimmune encephalitis
In a current consensus article, experts in the field of neurol-
ogy and neuroimmunology described the syndrome diagno-
sis of a possible AE. Accordingly, an autoimmune etiology 
should be considered if the following criteria are present:
1. Subacute onset (less than 3 months) of deficits in work-
ing memory, altered mental state (changes in conscious-
ness, changes in personality, or lethargy) or psychiatric 
(e.g., psychotic) symptoms.
2. One of the following findings:
• New focal neurological symptoms.
• New epileptic seizures.
• Magnetic resonance imaging (MRI) signs of 
“encephalitis” (temporal FLAIR hyperintensities, 
multifocal demyelinating or inflammatory lesions).
• Cerebrospinal fluid (CSF) pleocytosis (> 5 per  mm3).
3. Exclusion of other causes (see Table 4; [31]).
Established neuropsychiatric syndromes
From a clinical perspective, different established Ab-asso-
ciated neuropsychiatric syndromes with generally mixed 
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psychiatric and neurological symptoms can be identified 
(Table 1). In particular, limbic and anti-NMDA-R encephali-
tis are established central nervous system (CNS) syndromes 
that can go along with psychotic syndromes [31]. Various 
Ab-associated immunological systemic diseases, such as the 
prototype of neuropsychiatric systemic lupus erythematosus 
(NP-SLE), but also antiphospholipid syndrome, Sjögren’s 
syndrome, scleroderma, or (ANCA associated) vasculitis 
may also be associated with psychotic syndromes [63].
• Limbic encephalitis (LE): LE is characterized by the 
subacute development of deficits in working memory, 
paranoid symptoms, hallucinations, irritability, affective 
symptoms including emotional instability, and epileptic 
seizures with leading temporal semiology [68]. LE is 
often associated with specific Abs against cell surface 
antigens (e.g., LGI-1,  GABAB-R, and AMPA-R) or intra-
cellular antigens (e.g., GAD65, Hu, and Ma2 [31, 52]).
• Anti-NMDA-R encephalitis: This is the most common 
form of AE, and case series with > 500 patients are pub-
lished [86]. Tumor association depends on age and gen-
der: in children, tumor association is rare. By contrast, 
58% of women from 18 to 45 years suffered from para-
neoplastic forms, most commonly with ovarian teratomas 
[15, 86]. The symptoms usually develop in similar phases 
including psychotic/catatonic symptoms ([14, 15]; Fig. 1) 
or in case of relapses [44].
• Hashimoto’s encephalopathy/steroid-responsive 
encephalopathy associated with autoimmune thyroidi-
tis (SREAT): This is a nosologically unclear, probably 
etiologically heterogeneous syndromatic diagnosis based 
on the detection of antibodies against specific thyroid 
antigens (TPO, TG), non-specific paraclinical findings 
[e.g., blood–brain barrier (BBB) dysfunction in CSF, 
electroencephalography (EEG) slowing, MRI white 
matter lesions, after exclusion of antineuronal Abs in 
serum and CSF (including tissue-based assay)], and 
steroid responsiveness [22, 48]. Most authors argue that 
the thyroid Abs have no functional relevance, are rather 
indicators of an increased autoimmune susceptibility and 
that, therefore, this diagnosis will decrease with the fur-
ther discovery of new, specific antineuronal Abs. In line 
with these observations, a recent study indicates that the 
current criteria (see Table 1) do not allow a prediction 
of steroid responsiveness [57]. Better additional clinical, 
laboratory or instrumental-based diagnostic parameters 
as predictors of steroid response need to be explored; the 
criteria of Hashimoto’s encephalopathy must, therefore, 
be viewed critically [57].
• Neuropsychiatric SLE (NP-SLE): The clinical picture 
of NP-SLE is usually a mixed neurological and psychi-
atric presentation, with systemic signs often providing 
decisive diagnostic indications. However, rare cases 
may present primarily with a classical schizophreniform 
phenotype [54]. The American College of Rheumatol-
ogy (ACR) criteria are well established (Table 1), newer 
classification criteria such as the Systemic Lupus Col-
laborating Clinics (SLICC) criteria take laboratory find-
ings more into account (https ://www.rheum atolo gy.org/
Pract ice-Quali ty/Clini cal-Suppo rt/Crite ria/ACR-Endor 
sed-Crite ria; [66]).
Predominant and isolated autoimmune psychosis
In addition to the established main neuropsychiatric syn-
dromes, milder Ab-associated autoimmune disorders with 
predominant or even isolated schizophreniform psychosis 
have been described in individual cases [23–25, 27–29, 44, 
54, 56, 83]. For a subgroup of 23 out of 571 (4%) patients 
with anti-NMDA-R encephalitis, Kayser and colleagues 
described episodes with purely psychiatric presentations. 
Five patients developed an initial encephalitis with isolated 
Fig. 1  Typical course of anti-NMDA-R encephalitis [14, 15, 18, 22, 52, 70]
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psychotic symptoms (0.9%), and 18 patients (3.2%) had 
isolated psychiatric symptoms during a relapse [44]. In the 
meantime, cases with isolated anti-NMDA-R Ab detection 
in the serum and typical  [18F]fluorodeoxyglucose positron 
emission tomography (FDG-PET) alterations were pub-
lished [28]. In a case collection of 46 classic psychiatric 
Hashimoto encephalopathy cases, 12 patients suffered from 
acute psychosis (26.1%), and one patient met the criteria for 
schizophrenia (2.2%) [59]. Abs against intracellular antigens 
also may be associated with classical schizophreniform syn-
dromes in rare individual cases [24, 60]. Tissue-based assays 
helped to detect new antineuronal Abs with neuropil pattern 
and yet unspecified target epitopes [27]. For such psychiatric 
manifestations of AE, the concept of AP was suggested and 
consensus criteria for possible, probable, and definite AP 
have recently been proposed for the first time ([67]; Table 2).
Red flags that should lead to antibody diagnostics
The relatively rapid development of a psychotic syndrome, 
atypical and often polymorphic clinical symptoms and the 
presence of other neurological and/or medical symptoms are 
typical signs in autoimmune pathogenesis and thus should 
prompt broad Ab analyses [22]. Certain constellations in the 
course of the disease and typical additional findings should 
also trigger clinicians to consider the possibility of an AE/
AP (Fig. 2; [2, 22, 36, 67, 76, 77, 84, 85]).
Pathophysiology
Established antineuronal antibodies
Abs against neuronal epitopes can be divided into Abs 
against cell surface antigens, which are most frequently asso-
ciated with schizophreniform psychoses, and those against 
intracellular antigens [15, 36, 67].
• Abs against cell surface antigens These Abs bind to syn-
aptic receptors, ion channels, or other cell surface pro-
teins. This enables pathogenic Abs to lead to functional 
changes in electrophysiological signaling or synaptic 
transmission [8, 47, 68]. Therefore, they can have a direct 
pathogenic meaning. The exact pathophysiological pro-
cesses are partly understood. Ab formation can be tumor-
triggered. In addition, herpes simplex or other infections 
can act as triggers of the pathogenic process [4, 42]. 
Apart from that, Ab production can be the expression 
of autoimmune predisposition [15]. The initial hope that 
the anti-NMDA-R Abs at disease onset could provide an 
explanation for the glutamate hypothesis of schizophre-
nia [75, 87] could not be confirmed. Some of the largest 
Ab studies to date (with > 1000 schizophrenia patients), Ta
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which were limited to blood serum examinations, have 
shown similar prevalence rates of different Abs (across 
all Ab classes, especially IgA and IgM isotypes) in the 
serum of patients with schizophrenia and controls, pre-
dominantly with very low Ab titers [13, 33]. At the same 
time, Ab detection in CSF appears to be less frequently 
[26, 64]; in a study of 124 patients with schizophrenia 
spectrum disorders, even all CSF tests were negative for 
antibodies against NMDAR, AMPAR, CASPR2, LGI1, 
and  GABAA/BR [64].
• Abs against intracellular antigens Abs against non-
synaptic intracellular antigens (e.g., Hu) typically occur 
paraneoplastically and have no direct pathogenic effect. 
They merely represent an epiphenomenon of a systemic 
tumor-triggered immune process. The cause of the 
inflammatory brain damage is a misguided response of 
cytotoxic T cells [51, 79]. There are often early and irre-
versible structural neuronal damages [79]. Abs against 
synaptic intracellular antigens are the “stiff-person spec-
trum” Abs against GAD65 and amphiphysin [51]. Anti-
GAD65 Abs are more common idiopathically, and it has 
not been conclusively determined whether they have a 
pathogenetic significance or are only an epiphenomenon 
of another immune process [15].
Systemic “possibly antineuronal” antibodies
These Abs do not bind exclusively to neuronal structures 
and can also be found together with antineuronal Abs in the 
context of an autoimmune predisposition [52]. Antinuclear 
antibodies (ANAs) can bind to ubiquitous nuclear structures 
(e.g., ds-DNA), but also to NMDA receptors and activate 
them. Therefore, excitotoxicity mediated by an acute NMDA 
receptor as well as subacute activation of microglia cells 
can lead to the destruction of synapses [62]. Thyroid Abs 
also occurs in about 13% of the healthy population [31], 
and serum Ab titers do not clearly correlate with symptom 
expression [48]; therefore, most authors have regarded them 
as an epiphenomenon [22].
Diagnostic approach
Indication for antibody analyses
The indication for serum and CSF Ab analyses results from 
the above-mentioned red flags (Fig. 2). The following con-
siderations and operationalizations represent a kind of clini-
cal consent among the authors who are all active in clinical 
diagnosis and management of new onset psychiatric and in 
particular psychotic patients. In the authors’ opinion, Ab 
measurements should be performed at least in the following 
constellation (compare with [36, 61, 67, 76, 77, 82, 85]):
The combination of acute or peracute onset of a first schizophreni-
form psychotic episode OR psychotic symptoms after AE in the 
past AND according to Fig. 2:
 at least one typical clinical finding OR
 at least one sign of typical autoimmune course OR
 at least one typical examination finding [82, 85].
Fig. 2  Red flags that should 
lead to antibody diagnostics 
(according to [2, 5, 22, 36, 53, 
55, 61, 67, 74, 76, 77, 85]). 
EEG electroencephalography, 
MRI magnetic resonance imag-
ing
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All serum-Ab findings should be interpreted in the con-
text of extended history data, the clinical syndrome, and the 
examination findings (especially including CSF Ab testing; 
[51, 82, 85]). The following investigations are suggested for 
patients with potential immunological genesis [82, 85]:
• Extended history: Infections/infectious prodroms and 
tumors should be looked for as possible triggers of Ab 
production. Attention should also be paid to a predispo-
sition for immunological systemic diseases (presence of 
rheumatological diseases, inflammatory skin diseases, 
etc.). In addition, risk factors (such as earlier epileptic 
seizures, earlier episodes with encephalitides, infections), 
systemic signs (e.g., CNS or gastrointestinal symptoms), 
patient’s medication history (e.g., tolerability of antipsy-
chotics), and family history should be inquired into.
• Medical and neurological physical examination: The 
medical examination should focus on possible signs for 
autonomic dysfunction or feverish conditions. In addi-
tion, attention should be paid to newly occurring neuro-
logical symptoms such as dyskinesia, or myoclonus.
• Neuropsychological testing: Neuropsychological testing 
should be considered to objectify more subtle cognitive 
deficits and to establish an objective follow-up parameter. 
The corresponding diagnostics can be based on standards 
of the established German GENERATE network (https ://
gener ate-net.de/gener ate-sops.html), which recommends 
carrying out bedside screening tests such as the Mon-
treal Cognitive Assessment and extended tests such as 
the Test Battery for Attention Testing, Verbal Learning 
and Memory Test, Ray Rey-Osterrieth Complex Figure 
Test, or Frontal Assessment Battery, etc.
• Laboratory measurements: The basic parameters of 
CSF are very important for differential diagnostic con-
siderations. Pleocytosis or CSF-specific OCBs provide 
information about a possible inflammatory process in 
the CNS. Based on the level of pleocytosis, autoimmune 
and infectious inflammations can often be distinguished 
[69]. Autoimmune genesis is usually accompanied by 
mild pleocytosis (from ≥ 5 to 100 per  mm3; [31]), and the 
albumin quotient CSF/serum informs about the blood-
CSF-barrier function, which should be assessed using 
the Reiber scheme [39, 72]. Serological analyses should 
exclude hyponatremia, which can be associated with 
anti-LGI1 Abs [88]. Box 2 puts forward a proposal for 
a two-step Ab diagnostic approach (compare with [82]). 
The determination of CSF is more sensitive for some 
Abs against established neuronal surface antigens; up 
to 14% of patients with anti-NMDA-R encephalitis had 
anti-NMDA-R Abs only in CSF [32]. The determination 
of Abs in serum and CSF enables the calculation of Ab 
indices (normalized to the total IgG ratio CSF/blood and 
the BBB function; [92]). Infectious (e.g., viral encepha-
litis), toxic, and other causes should be excluded.
• EEG: It is a sensitive, although not very specific, tool in 
the diagnosis of AEs [48, 86]. EEG examinations should, 
therefore, be carried out on a low-threshold basis [82, 85].
• Imaging: In LEs, MRI diagnostics usually show mesiotem-
poral hyperintensities in the T2 or FLAIR sequences [35]. 
In AEs with Abs against neuronal cell surface antigens, 
MRI often remains inconspicuous [35, 86]. The follow-
ing sequences are suggested by the German GENERATE 
network: FLAIR axial + FLAIR coronary hippocampal 
view, T2 coronary, DWI axial and coronary, T2* axial or 
SWI, T1 + contrast agent axial, T1-MPRAGE (1 × 1 × 1 
mm; before contrast agent; https ://gener ate-net.de/gener 
ate-sops.html). If the findings remain unclear, an FDG-
PET examination can be considered for specific questions. 
Compared to MRI, FDG-PET possibly has higher sensitiv-
ity for inflammatory changes ([5, 28, 35]; Fig. 3).
• Tumor screening Tumor screening is essential in the 
event of the detection of paraneoplastic, onconeural 
antineuronal Abs.
Box 2: Methodological aspects and suggestions 
for two‑step antibody measurements
Basic measurement methods for the detection of 
antineuronal antibodies against cell surface antigens 
(especially against NMDA-R; [41, 47, 76, 77, 82, 85]):
• Screening tests: Commercially available cell-based 
assays (CBAs) using indirect immunofluorescence 
(IF) on fixed cells expressing synaptic or neuronal 
cell surface proteins (also called “biochip assays”) are 
often used for screening. These tests might be less sen-
sitive in patients with psychosis. However, they allow 
directly an exact detection of the target epitope.
• CBAs on live mammalian cells (so-called live CBAs) 
might show higher sensitivity for some surface anti-
bodies (e.g., AMPA-R-abs); however, they are cur-
rently available only in special laboratories.
• Tissue-based assays: IF or immunohistochemical 
screening tests on brain sections of rodents can also 
detect previously unknown Abs. With their appli-
cation, the percentage of “seronegative” cases is 
expected to decrease. Commercially available tissue-
based tests are considered to be less sensitive than 
research laboratory approaches.
Basic antibody screening for patients with schizo-
phreniform psychoses should contain at least the most 
common IgG antibodies against the following antigens 
[82]:
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Fig. 3  Findings of a 21-year-old 
female patient with probable 
anti-NMDA-R encephalitis. 
Magnetic resonance imaging 
depicted only a few slight, 
nonspecific bifrontal white 
matter lesions.  [18F]fluorode-
oxyglucose positron emission 
tomography showed pro-
nounced relative hypermetabo-
lism of her association cortices 
and a relative hypometabolism 
of the primary cortices (at base-
line), which quickly improved 
during the follow-up examina-
tion after anti-inflammatory 
treatment (©Endres et al., 2019, 
Front Neurol. Nov 5 [28]: https 
://www.front iersi n.org/artic 
les/10.3389/fneur .2019.01086 
/full)
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• NMDA-R, CASPR2, LGI1, AMPA-R,  GABAB-R, 
GAD65 (in serum and CSF).
• Hu, Ri, Yo, CV2/CRMP5, Ma2 [Ta], Amphiphysin 
(in serum, CSF testing can be added if the serum is 
positive).
• TPO, TG, ANA (in serum).
In the second step (in cases of negative screening 
and justified suspicion—compare Table 3), IgG anti-
bodies against the following antigens can be added 
[82]:  
• GABAA-R, DPPX, mGluR5, Neurexin-3-alpha, 
IgLON5, Glycin-R (in serum and CSF).
• Additional rheumatological examinations:
– In the case of positive ANA screening: Abs against 
dsDNA/ENA-differentiation (specification for 
Sm,nucleosome, etc.; in serum).
– ANCA (specification for MPO and PR3; in serum).
– Antiphospholipid Abs (anti-β2-Glykoprotein-I Abs, 
anticardiolipin Abs, lupus anticoagulant; in serum/
citrate tube).
Immunofluorescence screening tests on brain sec-
tions of rodents (“tissue-based assays”) can also detect 
previously unknown antineuronal antibodies.
For the second step, CSF material can be stored and 
cooled at 4 °C for at least four to 6 weeks; alternatively, 
the CSF material can be deep-frozen at − 80 °C [82].
*In line with the authors’ clinical experience, only the 
Abs most frequently associated with schizophreniform 
psychoses are mentioned.
Organic differential diagnosis
Primary forms of schizophreniform psychoses must be dis-
tinguished not only from secondary Ab-mediated AEs but 
also from other CNS diseases (Table 4).
Therapeutic experiences and considerations
For the treatment of AE/AP, not only are the classical symp-
tomatic therapy approaches available, but more causal ther-
apy options also exist with immunosuppressive agents and in 
case of paraneoplastic disease with tumor treatment. Immu-
nosuppressive and tumor therapy should be coordinated in 
a multidisciplinary setting [76, 77, 82]. Because controlled 
therapy studies are not yet available, immunosuppressive 
treatments have so far been carried out in the form of indi-
vidual therapy trials [79, 90].
Symptomatic treatment
The risk for extrapyramidal motor side effects seems to be 
increased in patients with AEs [49, 67, 76, 77]. Therefore, 
psychotic symptoms in the context of AP can be symptomat-
ically treated with antipsychotics with a low risk for motor 
side effects [76, 77]. Benzodiazepines can be used for anxi-
olysis and sedation and, in higher doses, for the treatment of 
catatonic symptoms [76, 77].
Causal immunosuppressive/tumor treatment
The first-line therapy for established AEs is high-dose ster-
oids (e.g., 500–1000 mg methylprednisolone over three to 
five days; [11, 76, 77, 82, 84]). Possible steroid-induced 
affective, suicidality, psychotic, and other side effects 
must be explained in advance [30] and closely monitored. 
Based on previous experiences, intravenous immuno-
globulins or plasmapheresis/immunoadsorption can also 
be used as a first-line treatment [31, 51, 58, 76, 77, 79]. 
Rituximab or cyclophosphamide are recommended as 
“escalation”/“second line” therapies [11, 31, 51, 58, 76, 77, 
79]. If relapse prevention turns out to be necessary, azathio-
prine, mycophenolate mofetil, or methotrexate are often used 
([51]; Fig. 4). The decision for immunomodulatory main-
tenance/relapse prevention therapies is often complicated, 
depending on several factors, and should, therefore, only be 
made after a multidisciplinary discussion and under regular 
follow-up investigations. Depending on the Ab type, slightly 
different approaches have been established, which cannot 
be discussed in detail here. The aim of tumor treatment in 
paraneoplastic syndromes is to switch off the ectopic anti-
gen source that maintains the autoimmune process ([79], 
Table 3).
Limitations
The recommendations worked out here for Abs assessment 
and respective diagnostic and therapeutic consequences in 
schizophreniform psychoses were based on consensus from 
emerging clinical evidence rather than from systematic ran-
domized studies as is the case with the present recommen-
dations for diagnosis and treatment of AE [31]. Beyond, 
it should be recognized that indeed both well-established 
clinical terms (like encephalitis, encephalopathy, neuroin-
flammation) and newly proposed terms (such as AP, AE) 
are hardly exactly defined, thus for clinical use typically 
represent just clinical case definitions based on respective 
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limited and steadily emerging clinical consensus [6, 12]. In 
addition, the possibility of underlying so far not identified 
new Abs is also limiting the whole issue. Finally, it should 
be pointed out again that low-positive serum antineuronal 
Ab titers without signs of brain involvement may occur non-
specifically and do not provide indication for treatment [13, 
33, 50, 67].
Conclusion
AE/AP represent a new field for psychiatry. The exact preva-
lence and thus clinical relevance of classical psychotic mani-
festations of AEs cannot yet be clearly established. However, 
the fact that predominant and even isolated psychotic clinical 
pictures may arise as a result of such AEs in certain cases is 
casuistically proven for most of the subtypes discussed here 
and already led to the first immunological treatment trials in 
Ab seropositive patients with psychosis [50]. Additionally, 
the topic has been captured in the new German S3 guide-
line for schizophrenia [20]. Future randomized-controlled 
and multimodal trials also taking into consideration CSF-
results and Ab-titers are needed to shed more light on the 
relationship between the Abs and the outcome of psychosis 
discussed here.
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Table 4  The most important organic differential diagnoses [31, 45, 81, 82, 84, 85]
Inflammatory disorders Non-inflammatory disorders
CNS infections (e.g., neuro-borreliosis, neuro-syphilis, Whipple’s dis-
ease, Herpes simplex virus encephalitis, HIV infection, Creutzfeldt-
Jakob disease)
Demyelinating CNS diseases (e.g., multiple sclerosis, acute dissemi-
nated encephalomyelitis); neuromyelitis optica-spectrum diseases
Other rheumatological diseases with brain involvement (e.g., neurosar-
coidosis, Behcet’s disease)
Primary/secondary CNS vasculitis
Other immunological diseases: Rasmussen encephalitis, CLIPPERS 
etc.
Progressive multifocal leukoencephalopathy (JC-Virus infection)
Intoxication (illegal drugs such as amphetamines or cannabis)
Inborn Errors of Metabolism (e.g., Niemann-Pick type C, acute inter-
mittent porphyria, phenylketonuria, glycogen storage disorders)
Mitochondriopathies
Congenital disorders (e.g., velocardiofacial syndrome, agenesis of 
corpus callosum)
Seizure disorders (e.g., temporal lobe epilepsy, paraepileptic psychoses)
Endocrinological diseases (e.g., Cushing’s disease, hypoparathyroidism, 
hyperparathyroidism)
Craniocerebral trauma
Vitamin deficiency (e.g., B1, folic acid, B12)
Toxic-metabolic causes (e.g., anticonvulsants, steroid treatment; 
hepatic/uremic encephalopathy)
Vascular hypoxic damage (strategic stroke lesions)
Neoplasias (e.g., gliomas, lymphomas, meningitis neoplastica)
Basal ganglia diseases (e.g., Parkinson’s disease, chorea minor, Wil-
son’s disease, pantothenate-kinase associated neurodegeneration, 
Huntington’s disease)
Neurodegenerative-dementia syndromes (e.g., frontotemporal dementia, 
Lewy body dementia etc.)
Creutzfeldt-Jakob disease
Fig. 4  Therapeutic experiences and considerations for patients with 
autoimmune encephalitides and established antineuronal antibodies 
[11, 51, 58, 76, 77, 79, 82]. However, in individual cases, special fea-
tures must be taken into account, depending on the individual autoan-
tibodies/syndromes/circumstances. *Rituximab is increasingly used 
as a first-line therapy. **Treatment with cyclophosphamide should be 
used only with caution in young patients because of the relevant germ 
cell damage
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The authors of this paper have already published several reviews on the 
topic ([11, 22, 51, 52, 68, 69, 70, 76, 77, 79, 82, 84, 85]). There may, 
therefore, be overlaps in wording compared to the other publications. 
In particular, the current paper is inspired by some articles that have 
recently been published in German [22, 82, 85].
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